Search

Your search keyword '"Lv, Yuqi"' showing total 15 results
Start Over Author "Lv, Yuqi"
15 results on '"Lv, Yuqi"'

4. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma

Author

Zhang, Qiqi, primary, Zu, Cheng, additional, Jing, Ruirui, additional, Feng, Youqin, additional, Zhang, Yanlei, additional, Zhang, Mingming, additional, Lv, Yuqi, additional, Cui, Jiazhen, additional, Zhou, Linhui, additional, Meng, Ye, additional, Wang, Linqin, additional, Cen, Zenan, additional, Chang, Alex H., additional, Hu, Yongxian, additional, and Huang, He, additional

Published
2023
Full Text
View/download PDF

6. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy

Author

Fu, Shan, Zhang, Qiqi, Jing, Ruirui, Zu, Cheng, Ni, Fang, Lv, Yuqi, Cui, Jiazhen, Zheng, Haiqiong, Zhang, Yanlei, Zhang, Mingming, Wei, Guoqing, Cen, Zenan, Chang, Alex H., Hu, Yongxian, and Huang, He

Abstract

B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). Concern of the safety and efficacy of CAR-T cell therapy in patients with chronic or resolved HBV infection is raised. In this study, we retrospectively reviewed 99 patients with r/r MM treated with BCMA-targeted CAR-T cell therapy, of which 7 (7.1%) patients had chronic HBV infection, 43 (43.4%) with resolved HBV infection, and the remaining 49 (49.49%) HBV-uninfected. Patients’ characteristics before CAR-T cell administration were comparable in different status of HBV infection. Patients’ liver function, cytokine levels, CAR-T cell expansion and cytokine release syndrome (CRS) grade after CAR-T cell therapy did not differ in different HBV serologic status. Furthermore, chronic HBV infection or resolved HBV infection did not affect clinical response, progress-free survival (PFS), or overall survival (OS). Four (4.04%) patients experienced HBV reactivation, 3 (6.98%) with resolved HBV infection, and 1 (14.29%) chronic HBV infection. Of 4 patients with HBV reactivation, 2 cases (50%) of severe hepatitis were noted and reported. Drops of serum IgG and elevation of alanine aminotransferase (ALT), alanine aminotransferase (AST), total bilirubin (TB) were observed in all four patients around the date of HBV reactivation.

Published
2023
Full Text
View/download PDF

15. A Meta-Analysis of Prognostic Factors in Patients with Posterior Circulation Stroke after Mechanical Thrombectomy.

Author

Xun K, Mo J, Ruan S, Dai J, Zhang W, Lv Y, Du N, Chen S, Shen Z, and Wu Y

Subjects
Aged, Aged, 80 and over, Female, Hospital Mortality trends, Humans, Ischemic Stroke diagnosis, Ischemic Stroke mortality, Male, Middle Aged, Quality Indicators, Health Care trends, Recovery of Function, Referral and Consultation trends, Retrospective Studies, Risk Assessment, Risk Factors, Thrombectomy adverse effects, Thrombectomy mortality, Time Factors, Time-to-Treatment trends, Treatment Outcome, COVID-19, Ischemic Stroke therapy, Outcome and Process Assessment, Health Care trends, Patient Admission trends, Practice Patterns, Physicians' trends, Thrombectomy trends
Abstract

Background: Posterior circulation stroke is characterized by poor prognosis because its optimal thrombolysis "time window" is always missed. After mechanical thrombectomy (MT), the recanalization rate of posterior circulation obstruction is significantly increased, but prognosis remains poor. To best manage patients, prognostic factors are needed to inform MT triaging after posterior circulation stroke., Methods: A systematic literature search was done for the period through April 2020. Studies included those with posterior circulation stroke cases that underwent MT. The primary outcome measure in this study was the modified Rankin Scale on day 90., Results: No outcome differences were found in gender, atrial fibrillation, smoking, and coronary artery disease (OR = 1.07, 95% CI: 0.90-1.28; OR = 1.02, 95% CI: 0.82-1.26; OR = 1.26, 95% CI: 0.94-1.68; and OR = 0.84, 95% CI: 0.58-1.22, respectively). Hypertension, diabetes mellitus, and previous stroke correlated with poorer prognosis (OR = 0.61, 95% CI: 0.48-0.77; OR = 0.60, 95% CI: 0.50-0.73; and OR = 0.74, 95% CI: 0.55-0.99, respectively). However, hyperlipidemia correlated with better prognosis (OR = 1.28, 95% CI: 1.04-1.58)., Conclusion: Our analysis indicates that hypertension, diabetes mellitus, or previous stroke correlate with poorer outcomes. Intriguingly, hyperlipidemia correlates with better prognosis. These factors may help inform triage decisions when considering MT for posterior circulation stroke patients. However, large, multicenter, randomized controlled trials are needed to validate these observations., (© 2020 S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results